PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma
What is the purpose of this trial?
To assess the 5-year progression-free survival (PFS) rate in patients with newly diagnosed limited stage diffuse large B-cell lymphoma using PET/CT scan to direct therapy after 3 cycles of R-CHOP
1) To evaluate progression-free survival within the PET+ and PET- subgroups of patients with newly diagnosed limited stage diffuse large B-cell lymphoma (DLBCL).
2) To evaluate toxicity of the protocol treatments in this patient population.
3) To evaluate the response probability in this patient population.
4) To evaluate overall survival in the overall population, and within the PET+ and PETsubgroups.
5) To estimate the rate of upstaging at baseline by PET/CT among patients newly diagnosed with limited stage diffuse large B-cell lymphoma by CT imaging and describe outcomes in patients upstaged by PET/CT at baseline to advanced DLBCL.
6) To describe outcomes in the subgroup of patients upstaged by PET/CT.7) To evaluate the association of germinal center B-cell subtype (GCB) vs. stromal-1 vs. stromal-2 gene expression signatures with PFS or overall survival (OS).
- 18 Years and older
- Southwestern Oncology Group (SWOG)
- September 2012
- Last Updated:
- Study HIC#:
Clinicaltrials.gov ID: Yale3293682